GB1211   Click here for help

GtoPdb Ligand ID: 11202

Synonyms: compound 11d [Zetterberg et al., 2022] | Example 44 [WO2016120403A1] | GB-1211
Compound class: Synthetic organic
Comment: GB1211 is an orally active small molecule galectin-3 inhibitor [1,5]. It was developed by Galecto Biotech for the treatment of fibrotic disease and cancer. In the fibrotic setting, blocking galectin-3's biological function is predicted to combat the enhanced TGF-β receptor-mediated macrophage differentiation and myofibroblast activation that drives pathological fibrotic changes [2-4].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 138.82
Molecular weight 532
XLogP 2.16
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES OCC1OC(Sc2cncc(c2)Br)C(C(C1O)n1nnc(c1)c1cc(F)c(c(c1)F)F)O
Isomeric SMILES OCC1OC(Sc2cncc(c2)Br)C(C(C1O)n1nnc(c1)c1cc(F)c(c(c1)F)F)O
InChI InChI=1S/C19H16BrF3N4O4S/c20-9-3-10(5-24-4-9)32-19-18(30)16(17(29)14(7-28)31-19)27-6-13(25-26-27)8-1-11(21)15(23)12(22)2-8/h1-6,14,16-19,28-30H,7H2
InChI Key FNCLKJPMEFPXOR-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
A planned clinical trial of GB1211 in non-alcoholic steatohepatitis (NASH; NCT04607655) was withdrawn before recruitment began. A study in non-small cell lung cancer (NSCLC) is continuing. In this latter trial, GB1211 will be evaluated in combination with the immuno-oncology (anti-PD-L1) therapeutic atezolizumab (Tecentriq®).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05240131 A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). Phase 1/Phase 2 Interventional Galecto Biotech AB
NCT05009680 A Single and Repeat Dose Trial in Participants With Hepatic Impairment Phase 1/Phase 2 Interventional Galecto Biotech AB